CD8A and neoplasm: Neotype neutrophil cytopharmaceuticals (NEs@STING-Mal-NP) activate the stimulator of interferon genes (STING) pathway, promoting macrophage and dendritic cell infiltration and boosting CD8+ T cell-mediated anti-tumor responses (Figure 5E) [150].